<DOC>
	<DOC>NCT00557466</DOC>
	<brief_summary>This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.</brief_summary>
	<brief_title>A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any studyrelated procedure (which include any adjustment to their current COPD treatment) Cooperative outpatients with a diagnosis of COPD (moderate to severe as classified by the Global Initiative for Obstructive Lung Disease (GOLD) Guidelines, 2006) and: Smoking history of at least 10 pack years Postbronchodilator Forced Expiratory Volume in one second (FEV1) &lt; 80% and ≥30% of the predicted normal value. Postbronchodilator FEV1/Forced vital capacity (FVC) &lt; 70% Pregnant women, nursing mothers, or females of childbearing potential, regardless of whether or not sexually active, if they are not using acceptable methods of contraception. Patients who have been hospitalized for an exacerbation of their airways disease within 6 weeks prior to Visit 1 or between Visit 1 and Visit 2. Patients with a history of asthma. Patients with an acute respiratory tract infection within 4 weeks prior to Visit 1, will be not allowed to enter the study. Other clinically significant conditions which may interfere with the study conduct or patient safety as specified in the protocol. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>QMF</keyword>
	<keyword>indacaterol</keyword>
	<keyword>TWISTHALER® device</keyword>
</DOC>